17

What is claimed is:

- 1. A therapeutic composition for symptomatic treatment of respiratory allergies in a warm-blooded animal, said composition comprising a pharmaceutically effective amount of diphenhydramine tannate at a consistent purity in substantial absence of an organic solvent and in solid dosage form.
- 2. The composition of claim 1, wherein said organic solvent is an alcohol.
- 3. The composition of claim 1, wherein said organic solvent is a mineral oil.
- 4. The composition of claim 1, wherein said organic solvent is isopropyl alcohol.
- 5. The composition of claim 1, wherein said organic solvent is glycerin.
- 6. The composition of claim 1, wherein said organic solvent is propylene glycol.
- 7. The composition of claim 1, wherein said organic solvent is ethanol.
- 8. The composition of claim 1, further including at least one additional active ingredient selected from a group consisting of antihistamines,

PCT/US03/05664

18

sympathomimetics, decongestants, cough suppressants, antitussives and expectorants.

WO 03/086356

5

- 9. A therapeutic composition for symptomatic treatment of respiratory allergies in a warm-blooded animal, said composition comprising a pharmaceutically effective amount of diphenhydramine tannate at a consistent purity in substantial absence of decomposition products of diphenhydramine produced at temperatures above about 50 degrees C and in solid dosage form.
- 10. The composition of claim 9 wherein said decomposition product is benzhydrol.
- 11. The composition of claim 9 wherein said decomposition product is benzophenone.
- 12. The composition of claim 9 wherein said decomposition product is diphenylchloromethane.
- 13. The composition of claim 9 wherein said decomposition product is dimethylaminoethanol.
- 14. The composition of claim 9 wherein said decomposition product is diphenylmethane.
- 15. The composition of claim 9 wherein said decomposition product is diphenyl alkyl ether.

- 16. The composition of claim 9, further including at least one additional active ingredient selected from a group consisting of antihistamines, sympathomimetics, decongestants, cough suppressants, antitussives and expectorants.
- 17. A therapeutic composition for symptomatic treatment of respiratory allergies in a warm-blooded animal, comprising a pharmaceutically effective amount of diphenhydramine tannate at a consistent purity prepared by:
- (a) dissolving the salt or free base of the diphenhydramine in a pharmaceutically acceptable liquid to form a solution at a maximum temperature and pH value, that does not cause decomposition of the active pharmaceutical ingredient;

5

10

15

- (b) separately mixing an anti-clumping agent with tannic acid to generate a blend;
- (c) combining the solution from step (a), with the blend of step (b) to form a tannate salt of diphenhydramine;
- (d) combining the tannate salt of the diphenhydramine of step (c) with a pharmaceutically acceptable excipient to form a granulate; and
- (e) processing the granulate into a tablet, capsule or other solid dosage form.
- 18. The composition of claim 17, further including at least one additional active ingredient selected from a group consisting of antihistamines, sympathomimetics, decongestants, cough suppressants, antitussives and expectorants.

- 19. A method for symptomatically treating respiratory allergies in a warm-blooded animal, comprising administering to said warm-blooded animal a pharmaceutically effective amount of diphenhydramine tannate at a consistent purity in substantial absence of an organic solvent and in solid dosage form.
- 20. A method for symptomatically treating respiratory allergies in a warm-blooded animal, comprising administering to said warm-blooded animal a pharmaceutically effective amount of diphenhydramine tannate at a consistent purity in substantial absence of decomposition products of diphenhydramine produced at temperatures above about 50 degrees C and in solid dosage form.

5

5

10

- 21. A method for symptomatically treating respiratory allergies in a warm-blooded animal, comprising administering to said warm-blooded animal a pharmaceutically effective amount of diphenhydramine tannate at a consistent purity prepared by:
- (a) dissolving the salt or free base of the diphenhydramine in a pharmaceutically acceptable liquid to form a solution at a maximum temperature and pH value, that does not cause decomposition of the active pharmaceutical ingredient;
- (b) separately mixing an anti-clumping agent with tannic acid to generate a blend;
- (c) combining the solution from step (a), with the blend of step (b) to form a tannate salt of diphenhydramine;
- (d) combining the tannate salt of the diphenhydramine of step (c) with a pharmaceutically acceptable excipient to form a granulate; and

- (e) processing the granulate into a tablet, capsule or other solid dosage form.
- 22. The composition of claim 1 in substantial absence of any other active ingredient.
- 23. The composition of claim 1 in substantial absence of any other tannate salt.
- 24. The composition of claim 9 in substantial absence of any other active ingredient.
- 25. The composition of claim 9 in substantial absence of any other tannate salt.
- 26. The composition of claim 17 in substantial absence of any other active ingredient.
- 27. The composition of claim 17 in substantial absence of any other tannate salt.